DavidMO'MalleyMD

Gynecologic Oncology

Professor of Obstetrics & Gynecology The Ohio State University and James CCC; Director, Clinical Research Gynecologic Oncology; ORIEN Physician Liaison for OSUCCC-James

Join to view full profile

Dr. O'Malley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. O'Malley's full profile

Already have an account?

Office
3651 Ridge Mill Dr
OSU Dept Obstetrics/Gynecology, M210 Starling Loving Hall
Hilliard, OH 43026
Phone+1 614-293-3873

Fax+1 614-293-3078

Education & Training

Yale-New Haven Medical CenterFellowship, Gynecologic Oncology, 2002 - 2005
The MetroHealth System/Case Western Reserve UniversityResidency, Obstetrics and Gynecology, 1998 - 2002
Cleveland Clinic FoundationResidency, Obstetrics and Gynecology, 1998 - 2002
Wayne State University School of MedicineClass of 1998
University of Notre DameBA, Pre-Med, 1989 - 1992

Certifications & Licensure

OH State Medical License 2005 - 2026
CT State Medical License 2002 - 2006
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma Start of enrollment: 2007 Aug 01
Completed
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01
Unknown status
Not Applicable
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
Completed
Phase 1
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 1
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Completed
Phase 1
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Start of enrollment: 2011 Jun 01
Completed
Phase 2
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection Start of enrollment: 2012 Jan 03
Active, not recruiting
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Start of enrollment: 2012 Jun 28
Completed
Phase 1
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 3
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Biomarkers for Gynecologic Cancer Start of enrollment: 2014 Jun 01
Unknown status
Study of AGEN2034 in Advanced Tumors and Cervical Cancer Start of enrollment: 2017 Apr 11
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

65 citations
Low-grade serous ovarian cancer: State of the science
Brian M. Slomovitz, Charlie Gourley, Mark S. Carey, Anais Malpica, Ie Ming Shih
Gynecologic Oncology. 2020-01-20
274 citations
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Fact...
Amanda N. Fader, Dana M. Roque, Eric R. Siegel, Natalia Buza, Pei Hui
Journal of Clinical Oncology. 2018-03-27
73 citations
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
Casey M. Cosgrove, David E. Cohn, Heather Hampel, Wendy L. Frankel, Dan Jones
Gynecologic Oncology. 2017-09-01

Journal Articles

Phase Ib Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Pl...
David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lainie P Martin, Kathleen N Moore, Gynecologic Oncology

Lectures

Mirvetuximab soravtansine, a folate receptor alpha (FRÎ±)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resi...
2019 ASCO Annual Meeting - 6/1/2019
Mirvetuximab soravtansine, a folate receptor alpha (FR±)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resis...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

David O'Malley, MD, on Dual Immunotherapy for Advanced Cervical CancerMarch 9th, 2022
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with AvastinMay 15th, 2019
ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with AvastinMay 16th, 2018